Home › Research › Risk genes beyond APOE
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade E, Voytyuk I, Aisen P, Bateman RJ, Carrillo MC, De Strooper B, Haass C, Reiman EM et al.. Nature reviews. Neurology, 2021-09-21
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer disease (AD) is the most common cause of dementia in older individuals (>65 years) and has a long presymptomatic phase. Preventive therapies for AD are not yet available, and potential disease-modifying therapies targeting amyloid-β plaques in symptomatic stages of AD have only just been approved in the United States. Small-molecule inhibitors of β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1; also known as β-secretase 1) reduce the production of amyloid-β peptide and are among the most advanced drug candidates for AD.
What this study adds
Evidence grade: Low
This is a narrative review. This review argues for low-level inhibition of BACE1 as a possible way to prevent Alzheimer's disease by reducing amyloid-beta production. However, it notes that all phase II and phase III clinical trials of BACE inhibitors to date have failed, so no preventive therapy is yet available.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
McDade, E., Voytyuk, I., Aisen, P., Bateman, R. J., Carrillo, M. C., De Strooper, B., et al. (2021). The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature reviews. Neurology. https://doi.org/10.1038/s41582-021-00545-1
Vancouver
McDade E, Voytyuk I, Aisen P, Bateman RJ, Carrillo MC, De Strooper B, et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature reviews. Neurology. 2021. doi:10.1038/s41582-021-00545-1. PMID: 34548654.
BibTeX
@article{mcdade2021-34548654,
author = {McDade, E. and Voytyuk, I. and Aisen, P. and Bateman, R. J. and Carrillo, M. C. and De Strooper, B. and Haass, C. and Reiman, E. M. and others},
title = {{The case for low-level BACE1 inhibition for the prevention of Alzheimer disease}},
journal = {Nature reviews. Neurology},
year = {2021},
doi = {10.1038/s41582-021-00545-1},
pmid = {34548654},
url = {https://doi.org/10.1038/s41582-021-00545-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Preventive therapies for AD are not yet available, and potential disease-modifying therapies targeting amyloid-β plaques in symptomatic stages of AD have only just been approved in the United States.
- Small-molecule inhibitors of β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1; also known as β-secretase 1) reduce the production of amyloid-β peptide and are among the most advanced drug candidates for AD.
- However, to date all phase II and phase III clinical trials of BACE inhibitors were either concluded without benefit or discontinued owing to futility or the occurrence of adverse effects.
- Adverse effects included early, mild cognitive impairment that was associated with all but one inhibitor; preliminary results suggest that the cognitive effects are non-progressive and reversible.
Why it matters
This review argues for low-level inhibition of BACE1 as a possible way to prevent Alzheimer's disease by reducing amyloid-beta production. However, it notes that all phase II and phase III clinical trials of BACE inhibitors to date have failed, so no preventive therapy is yet available.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 51/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nature reviews. Neurology) |
| Journal's citation record | 3 / 4 | Nature Reviews Neurology: journal h-index 269 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 139 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 19.9 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 3 / 6 | Cited 4.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 3 / 4 | Cited 79 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Stefan F. Lichtenthaler: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 22 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34548654) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41582-021-00545-1
- PubMed: 34548654
- Original source →
- Free full text: Lirias (KU Leuven) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 25.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Risk genes beyond APOE from nearby years
Also in Risk genes beyond APOE
106 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.